BEDMINSTER, N.J.--(BUSINESS WIRE)--EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced it has commenced shipments of double (2X) concentration Cardene® I.V. (nicardipine hydrochloride) Premixed Injection.
